Brief reportAnalysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials
References (39)
- et al.
Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
J Am Coll Cardiol
(1988) - et al.
European Stroke Prevention Study 2Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
J Neurol Sci
(1996) - et al.
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectorisThe Swedish Angina Pectoris Aspirin Trial (SAPAT) Group
Lancet
(1992) - et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialHOT Study Group
Lancet
(1998) - et al.
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trialASA and Carotid Endarterectomy (ACE) Trial Collaborators
Lancet
(1999) - et al.
Ticlopidine versus Aspirin after Myocardial Infarction (STAMI) trial
J Am Coll Cardiol
(2001) - et al.
Risk of bleeding complications with antiplatelet agents: a meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials
Am J Hematol
(2004) Effect of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation
N Engl J Med
(2001)- et al.
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study
Circulation
(2003) - et al.
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
Circulation
(2003)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
BMJ
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
N Engl J Med
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
N Engl J Med
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
Lancet
Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
Lancet
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice
Lancet
Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes
Circulation
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial
Lancet
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
Lancet
Cited by (304)
The impact of pre-stroke aspirin exposure on radiographic appearance and disability outcomes: A post-hoc analysis of the SPS3 trial: Aspirin Use and Small Subcortical Stroke
2024, Journal of Stroke and Cerebrovascular DiseasesAdherence to European guidelines for the use of aspirin in primary health care
2023, Revista Portuguesa de CardiologiaAntiplatelet Agents in Acute ST Elevation Myocardial Infarction
2022, American Journal of MedicineCitation Excerpt :Furthermore, Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions (CURRENT-OASIS 7)14 did not show any difference with respect to primary endpoint of cardiovascular death, myocardial infarction (MI), or stroke based on ASA dosing. Similar results are also seen in meta-analysis involving 31 trials15 as well as in subgroup analysis involving Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS AMI)16 and Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE ACS)17 trials, which showed similar reductions in cardiovascular events with high- or low-dose aspirin and similar or greater risks of bleeding with higher doses of ASA. In summary, based on the clinical trial data, current ACC/AHA guidelines recommend ASA 81-325 mg indefinitely after percutaneous coronary intervention (PCI; Class I, Level of Evidence [LOE] A).
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022, Journal of the American College of Cardiology
- ⁎
Drs. Serebruany and Topol are consultants for McNeil Consumer & Specialty Pharmaceuticals. This study was not funded by McNeil.